Rineterkib

SKU: orb1309691

Description

ERK-IN-1 (Rineterkib) is a selective small molecule inhibitor targeting RAF and ERK1/2 kinases within the MAPK signaling cascade. It is utilized in preclinical research to investigate oncogenic pathways and has demonstrated activity in both cellular assays and in vivo models of cancer.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1715025-32-3
• MW: 578.42
• Purity: 99.73% (May vary between batches)
• Formula: C₂₆H₂₇BrF₃N₅O₂
• SMILES: CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1
• Target: Raf,ERK
• Solubility: DMSO:60 mg/mL (103.73 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.64 mM)

Bioactivity

• In Vivo:
  ERK-IN-1 (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

KRAS, inhibit, NSCLC, MAPK, Inhibitor, G12C, G12D, G12V, ERK, ERK1, ERK2, ERK-IN-1, Extracellular signal regulated kinases, Rineterkib, Raf kinases, RAF, Raf

Compound Identifiers

PubChem CID

118045847